Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

hed that starting with cohort 2, PCI-32765 fully occupied the target kinase. Examining response in fully occupied dose cohorts the response rate ("RR") was 56% in the evaluable patient population and 48% in the ITT patient population. Including disease control in the form of stable disease in our assessment of evaluable patients, the disease control rate was 78% (10% CRs, 41% PRs and 27% SDs). Of note, the median tumor reduction from base line in our objective responding patients was 75% as of August 31, 2010.  
  • As of August 31, 2010, 23 patients continue to remain on study. This compares with 25 patients on study as of the ASCO presentation on June 4, 2010.  Median duration of response has not yet been determined in this ongoing study. The company has submitted an abstract describing the duration of response to the American Society of Hematology (ASH) in Orlando, FL on December 4-7, 2010; consistent with ASH's guidelines, we will not be disclosing these data prior to our ASH presentation.
  • PCI-32765 appears to be well tolerated through the initial exposure even in its highest dosing cohort (including 12.5 mg/kg). Only 2 patients of the enrolled 47 patients have experienced a dose limiting toxicity (DLT) on this trial (drug hypersensitivity and delay in dosing due to neutropenia for 7 days). No other DLTs have been observed. Thirteen of the 47 patients had 1 or more serious adverse events, but only 2 were considered drug related by investigators.
  • As previously announced we have initiated a Phase Ib trial in CLL/SLL patients studying 2 populations. One population is relapsed or refractory patients at 420 mg (24 patients with fixed dosing). The second population is elderly naive patients at 420 mg (12 patients with fixed dosing). Enrollment commenced end of May and as of to date we have dosed 30 patients (22/24 in the 420 mg relapsed or refractory dosed arm and 8/12 elderly naive patients). Amongst all patients dosed we maintain a ben
    '/>"/>

  • SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
    (Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
    (Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
    Breaking Medicine Technology:CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
    ... Mich. , May 4 Stryker‘s Communications ... have signed an agreement to integrate both companies’ technologies ... this collaboration, operating rooms containing the da ... System will provide surgeons and OR staff more flexibility ...
    ... Two Roche employees were recognized for their significant ... TWIN Awards Dinner held April 29 , 2010.  Honored were ... M. Fieldstad , Pharm.D., global head, Safety Compliance, Pharmaceutical Development Safety and ... "These women ...
    Cached Medicine Technology:Stryker Enters Strategic Marketing Agreement With Intuitive Surgical 2Stryker Enters Strategic Marketing Agreement With Intuitive Surgical 3Roche Women Honored as 2010 TWIN Awardees 2Roche Women Honored as 2010 TWIN Awardees 3Roche Women Honored as 2010 TWIN Awardees 4Roche Women Honored as 2010 TWIN Awardees 5
    (Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
    (Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
    (Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
    (Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
    (Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
    Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
    ... P&C Industry Transactions Gateway Multiplies Direct Connectivity with ... States Move to Adopt eBill Regulations CONCORD, ... Property and Casualty industry supplier of EDI Gateway ... providers and payers nationwide. Network expansion enables Jopari ...
    ... O,Rourke, MD, Associate Professor of Neurosurgery at the University ... to accurately predict the specific genetic mutation that caused ... magnetic resonance imaging (MRI). The researchers presented their findings ... 100th Annual Meeting 2009. , "The field of cancer ...
    ... in poor areas more of an issue than youngsters, tastes, ... nutrition may be more an issue of supply than demand ... A new study found that children in these rural areas ... research shows these products are not readily available and could ...
    ... 2009) New research published in the April issue ... Surgeons suggests that, among surgeons inexperienced in laparoscopic ... less time to learn and results in improved outcomes ... with freehand laparoscopy. , Laparoscopic suturing a ...
    ... April 15, 2009, ten members of the American Society of ... attended more than a dozen meetings scheduled with key Congressional ... of transplant related issues on Capitol Hill. The Fly ... , AST discussed healthcare ...
    ... In study on rats, protection eludes those exposed as ... and the estrogen hormone they produce might help protect ... caused by the active ingredient in marijuana, Louisiana State ... , The protection did not seem to apply, ...
    Cached Medicine News:Health News:Jopari Further Expands Nationwide Medical Billing Network Connectivity for Workers' Comp and Auto Providers and Payers 2Health News:Jopari Further Expands Nationwide Medical Billing Network Connectivity for Workers' Comp and Auto Providers and Payers 3Health News:First noninvasive technique to accurately predict mutations in human brain tumors 2Health News:Kids and Veggies: Offer Them and They Will Eat 2Health News:Robot improves suture proficiency more rapidly for surgeons inexperienced in laparoscopic techniques 2Health News:Robot improves suture proficiency more rapidly for surgeons inexperienced in laparoscopic techniques 3Health News:AST Leaders Fly to Capitol Hill to Garner and Secure Support for Transplantation Initiatives 2Health News:Estrogen May Combat Marijuana's Effect on Cognition 2
    ... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
    ... mm. Storz offers the original Scleral ... A. Lincoff, M.D. The material is ... non-toxic and non-antigenic. Implants are soft ... intrusion. These implants are packaged sterile ...
    For use under curved implants. Indications: When additional buckling is required in the meridional direction. Overall length: 15.0 mm....
    For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
    Medicine Products: